Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

20171,221 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 390, Issue 10105, pp. 1853-1862

Field-Weighted Citation Impact: 67.34